Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-year SAFEHEART registry follow-up

L. Perez De Isla; R. Alonso; Gerald Watts; N. Mata; A. Saltijeral Cerezo; O. Muñiz; F. Fuentes; J.L. Diaz-Diaz; R. De Andrés; D. Zambón; P. Rubio-Marin; M.A. Barba-Romero; P. Saenz; J.F. Sanchez Muñoz-Torrero; C. Martinez-Faedo; J.P. Miramontes-Gonzalez; L. Badimón; P. Mata; R. Aguado; F. Almagro; F. Arrieta; M.Á. Barba; Á. Brea; J.M. Cepeda; G. Díaz; J.L. Díaz; J.A. Garrido; L. Irigoyen; L. Manjón; A. Martin; M. Piedecausa; M. Mauri; P. Miramontes; F. Pereyra; L. Pérez; X. Pintó; P. Pujante; E. Ruiz; J.F. Sánchez; J.I. Vidal; R. Argüeso

doi:10.1016/j.jacc.2016.01.008

Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-year SAFEHEART registry follow-up

L. Perez De Isla, R. Alonso, Gerald Watts, N. Mata, A. Saltijeral Cerezo, O. Muñiz, F. Fuentes, J.L. Diaz-Diaz, R. De Andrés, D. Zambón, P. Rubio-Marin, M.A. Barba-Romero, P. Saenz, J.F. Sanchez Muñoz-Torrero, C. Martinez-Faedo, J.P. Miramontes-Gonzalez, L. Badimón, P. Mata, R. Aguado, F. AlmagroF. Arrieta, M.Á. Barba, Á. Brea, J.M. Cepeda, G. Díaz, J.L. Díaz, J.A. Garrido, L. Irigoyen, L. Manjón, A. Martin, M. Piedecausa, M. Mauri, P. Miramontes, F. Pereyra, L. Pérez, X. Pintó, P. Pujante, E. Ruiz, J.F. Sánchez, J.I. Vidal, R. Argüeso

Graduate Research School

Research output: Contribution to journal › Article › peer-review

221 Citations (Scopus)

Abstract

© 2016 American College of Cardiology Foundation. Background Familial hypercholesterolemia (FH) is the most common genetic disorder associated with premature atherosclerotic cardiovascular disease (ASCVD). There are sparse data on attainment of treatment targets; large registries that reflect real-life clinical practice can uniquely provide this information. Objectives We sought to evaluate the achievement of low-density lipoprotein cholesterol (LDL-C) treatment goals in FH patients enrolled in a large national registry. Methods The SAFEHEART study (Spanish Familial Hypercholesterolemia Cohort Study) is a large, ongoing registry of molecularly defined patients with heterozygous FH treated in Spain. The attainment of guideline-recommended plasma LDL-C goals at entry and follow-up was investigated in relation to use of lipid-lowering therapy (LLT). Results The study recruited 4,132 individuals (3,745 of whom were ≥18 years of age); 2,752 of those enrolled were molecularly diagnosed FH cases. Mean follow-up was 5.1 ± 3.1 years; 71.8% of FH cases were on maximal LLT, and an LDL-C treatment target

Original language	English
Pages (from-to)	1278-1285
Number of pages	8
Journal	Journal of the American College of Cardiology
Volume	67
Issue number	11
DOIs	https://doi.org/10.1016/j.jacc.2016.01.008
Publication status	Published - 22 Mar 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jacc.2016.01.008Licence: Other

Cite this

Perez De Isla, L., Alonso, R., Watts, G., Mata, N., Saltijeral Cerezo, A., Muñiz, O., Fuentes, F., Diaz-Diaz, J. L., De Andrés, R., Zambón, D., Rubio-Marin, P., Barba-Romero, M. A., Saenz, P., Sanchez Muñoz-Torrero, J. F., Martinez-Faedo, C., Miramontes-Gonzalez, J. P., Badimón, L., Mata, P., Aguado, R., ... Argüeso, R. (2016). Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-year SAFEHEART registry follow-up. Journal of the American College of Cardiology, 67(11), 1278-1285. https://doi.org/10.1016/j.jacc.2016.01.008

@article{a19b135b080a48b79dfe8aa965ea082c,

title = "Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-year SAFEHEART registry follow-up",

abstract = "{\textcopyright} 2016 American College of Cardiology Foundation. Background Familial hypercholesterolemia (FH) is the most common genetic disorder associated with premature atherosclerotic cardiovascular disease (ASCVD). There are sparse data on attainment of treatment targets; large registries that reflect real-life clinical practice can uniquely provide this information. Objectives We sought to evaluate the achievement of low-density lipoprotein cholesterol (LDL-C) treatment goals in FH patients enrolled in a large national registry. Methods The SAFEHEART study (Spanish Familial Hypercholesterolemia Cohort Study) is a large, ongoing registry of molecularly defined patients with heterozygous FH treated in Spain. The attainment of guideline-recommended plasma LDL-C goals at entry and follow-up was investigated in relation to use of lipid-lowering therapy (LLT). Results The study recruited 4,132 individuals (3,745 of whom were ≥18 years of age); 2,752 of those enrolled were molecularly diagnosed FH cases. Mean follow-up was 5.1 ± 3.1 years; 71.8% of FH cases were on maximal LLT, and an LDL-C treatment target",

author = "{Perez De Isla}, L. and R. Alonso and Gerald Watts and N. Mata and {Saltijeral Cerezo}, A. and O. Mu{\~n}iz and F. Fuentes and J.L. Diaz-Diaz and {De Andr{\'e}s}, R. and D. Zamb{\'o}n and P. Rubio-Marin and M.A. Barba-Romero and P. Saenz and {Sanchez Mu{\~n}oz-Torrero}, J.F. and C. Martinez-Faedo and J.P. Miramontes-Gonzalez and L. Badim{\'o}n and P. Mata and R. Aguado and F. Almagro and F. Arrieta and M.{\'A}. Barba and {\'A}. Brea and J.M. Cepeda and G. D{\'i}az and J.L. D{\'i}az and J.A. Garrido and L. Irigoyen and L. Manj{\'o}n and A. Martin and M. Piedecausa and M. Mauri and P. Miramontes and F. Pereyra and L. P{\'e}rez and X. Pint{\'o} and P. Pujante and E. Ruiz and J.F. S{\'a}nchez and J.I. Vidal and R. Arg{\"u}eso",

year = "2016",

month = mar,

day = "22",

doi = "10.1016/j.jacc.2016.01.008",

language = "English",

volume = "67",

pages = "1278--1285",

journal = "Journal of the American College of Cardiology",

issn = "0735-1097",

publisher = "Academic Press",

number = "11",

}

Perez De Isla, L, Alonso, R, Watts, G, Mata, N, Saltijeral Cerezo, A, Muñiz, O, Fuentes, F, Diaz-Diaz, JL, De Andrés, R, Zambón, D, Rubio-Marin, P, Barba-Romero, MA, Saenz, P, Sanchez Muñoz-Torrero, JF, Martinez-Faedo, C, Miramontes-Gonzalez, JP, Badimón, L, Mata, P, Aguado, R, Almagro, F, Arrieta, F, Barba, MÁ, Brea, Á, Cepeda, JM, Díaz, G, Díaz, JL, Garrido, JA, Irigoyen, L, Manjón, L, Martin, A, Piedecausa, M, Mauri, M, Miramontes, P, Pereyra, F, Pérez, L, Pintó, X, Pujante, P, Ruiz, E, Sánchez, JF, Vidal, JI & Argüeso, R 2016, 'Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-year SAFEHEART registry follow-up', Journal of the American College of Cardiology, vol. 67, no. 11, pp. 1278-1285. https://doi.org/10.1016/j.jacc.2016.01.008

TY - JOUR

T1 - Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-year SAFEHEART registry follow-up

AU - Perez De Isla, L.

AU - Alonso, R.

AU - Watts, Gerald

AU - Mata, N.

AU - Saltijeral Cerezo, A.

AU - Muñiz, O.

AU - Fuentes, F.

AU - Diaz-Diaz, J.L.

AU - De Andrés, R.

AU - Zambón, D.

AU - Rubio-Marin, P.

AU - Barba-Romero, M.A.

AU - Saenz, P.

AU - Sanchez Muñoz-Torrero, J.F.

AU - Martinez-Faedo, C.

AU - Miramontes-Gonzalez, J.P.

AU - Badimón, L.

AU - Mata, P.

AU - Aguado, R.

AU - Almagro, F.

AU - Arrieta, F.

AU - Barba, M.Á.

AU - Brea, Á.

AU - Cepeda, J.M.

AU - Díaz, G.

AU - Díaz, J.L.

AU - Garrido, J.A.

AU - Irigoyen, L.

AU - Manjón, L.

AU - Martin, A.

AU - Piedecausa, M.

AU - Mauri, M.

AU - Miramontes, P.

AU - Pereyra, F.

AU - Pérez, L.

AU - Pintó, X.

AU - Pujante, P.

AU - Ruiz, E.

AU - Sánchez, J.F.

AU - Vidal, J.I.

AU - Argüeso, R.

PY - 2016/3/22

Y1 - 2016/3/22

N2 - © 2016 American College of Cardiology Foundation. Background Familial hypercholesterolemia (FH) is the most common genetic disorder associated with premature atherosclerotic cardiovascular disease (ASCVD). There are sparse data on attainment of treatment targets; large registries that reflect real-life clinical practice can uniquely provide this information. Objectives We sought to evaluate the achievement of low-density lipoprotein cholesterol (LDL-C) treatment goals in FH patients enrolled in a large national registry. Methods The SAFEHEART study (Spanish Familial Hypercholesterolemia Cohort Study) is a large, ongoing registry of molecularly defined patients with heterozygous FH treated in Spain. The attainment of guideline-recommended plasma LDL-C goals at entry and follow-up was investigated in relation to use of lipid-lowering therapy (LLT). Results The study recruited 4,132 individuals (3,745 of whom were ≥18 years of age); 2,752 of those enrolled were molecularly diagnosed FH cases. Mean follow-up was 5.1 ± 3.1 years; 71.8% of FH cases were on maximal LLT, and an LDL-C treatment target

AB - © 2016 American College of Cardiology Foundation. Background Familial hypercholesterolemia (FH) is the most common genetic disorder associated with premature atherosclerotic cardiovascular disease (ASCVD). There are sparse data on attainment of treatment targets; large registries that reflect real-life clinical practice can uniquely provide this information. Objectives We sought to evaluate the achievement of low-density lipoprotein cholesterol (LDL-C) treatment goals in FH patients enrolled in a large national registry. Methods The SAFEHEART study (Spanish Familial Hypercholesterolemia Cohort Study) is a large, ongoing registry of molecularly defined patients with heterozygous FH treated in Spain. The attainment of guideline-recommended plasma LDL-C goals at entry and follow-up was investigated in relation to use of lipid-lowering therapy (LLT). Results The study recruited 4,132 individuals (3,745 of whom were ≥18 years of age); 2,752 of those enrolled were molecularly diagnosed FH cases. Mean follow-up was 5.1 ± 3.1 years; 71.8% of FH cases were on maximal LLT, and an LDL-C treatment target

U2 - 10.1016/j.jacc.2016.01.008

DO - 10.1016/j.jacc.2016.01.008

M3 - Article

C2 - 26988947

SN - 0735-1097

VL - 67

SP - 1278

EP - 1285

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

IS - 11

ER -

Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-year SAFEHEART registry follow-up

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this